Tier 2 — strong

The Impact of Three-Month Quercetin Intake on Quality of Life and Anxiety in Patients With Type II Diabetes Mellitus: An Early Data Analysis From a Randomized Controlled Trial

Aikaterini E Mantadaki, Manolis Linardakis, Marina Vafeiadi, Foteini Anastasiou, Aristidis Tsatsakis, Emmanouil K Symvoulakis
Cureus 2024 16(4):e58219

Bibliography

PubMed
PMID 38745810
PubMed Central
PMC11091546
DOI
10.7759/cureus.58219
Funding
Reported funding/support: All authors have declared that no financial support was received from any organization for the submitted work. This research obtained no external funding. However, we received a free-of-charge donation of 152 quercetin supplement containers from Green Import, Exclusive Lamberts Healthcare LTD distributor, Greece, which we would like to thank. The company did not interfere in the design and execution of the study, and the results reflect the opinion of the authors.
Competing interests
Reported disclosure: The authors have declared that no competing interests exist.

Study snapshot

DesignInterim analysis of a randomized open-label usual-care controlled trial
ModelHuman intervention research
Sample38 participants in interim analysis: 20 intervention and 18 control
InterventionQuercetin 500 mg/day plus usual diabetes care
DurationFirst 12 weeks of a longer parent trial
EndpointsBlood pressure; Cognitive, mood, or sleep measures

What the study showed, in plain terms

Published in 2024, this source examined cardiovascular and metabolic health. Design: Interim analysis of a randomized open-label usual-care controlled trial. Sample/model: 38 participants in interim analysis: 20 intervention and 18 control. The exposure or intervention was Quercetin 500 mg/day plus usual diabetes care. Follow-up or treatment period: First 12 weeks of a longer parent trial.

Anxiety and quality-of-life scores improved, while blood pressure, waist, sleep and respiratory differences were not significant at this interim point.

Small interim subset and open-label self-report. Companion papers from the same trial are not independent confirmations.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Anxiety and quality-of-life scores improved, while blood pressure, waist, sleep and respiratory differences were not significant at this interim point.
  • The recorded outcome domains were Blood pressure; Cognitive, mood, or sleep measures.
  • The result applies to the tested exposure: Quercetin 500 mg/day plus usual diabetes care; First 12 weeks of a longer parent trial.

What this study can and cannot tell us

  • Small interim subset and open-label self-report. Companion papers from the same trial are not independent confirmations.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Benefits of Quercetin on Glycated Hemoglobin, Blood Pressure, PiKo-6 Readings, Night-Time Sleep, Anxiety, and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Aikaterini E Mantadaki et al. · Journal of clinical medicine · 2024
Tier 2
Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study
Aikaterini E Mantadaki et al. · Pharmaceuticals (Basel, Switzerland) · 2024
Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology